Ginkgo Bioworks Holdings, Inc. (DNA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DNA SEC filings page.
Ginkgo Bioworks Holdings, Inc. (DNA) reported $132.4M in revenue over the twelve months to Jun 30, 2026, down 37.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business is shrinking while cost reductions narrow losses, but operations still consume cash and equity has thinned.
Between FY2023 and FY2025, revenue fell from$251M to$170M while operating losses narrowed from$864M to$315M ; this points to expense contraction, not expanding commercial scale, as the main reason reported operating performance improved. The better loss figures therefore do not yet represent operating leverage from growth.
In FY2025, operating cash flow was
Total liabilities were
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Ginkgo Bioworks Holdings, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Ginkgo Bioworks Holdings, Inc. held $422.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $171.1M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Ginkgo Bioworks Holdings, Inc. scores 55/100 among other emerging companies.
Ginkgo Bioworks Holdings, Inc. had 58M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Ginkgo Bioworks Holdings, Inc. scores 52/100 among other emerging companies.
Ginkgo Bioworks Holdings, Inc. spent $243.8M on research and development in fiscal year 2025, which was 50.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Ginkgo Bioworks Holdings, Inc. scores 77/100 among other emerging companies.
Ginkgo Bioworks Holdings, Inc. reported revenue of $170.2M in fiscal year 2025, against $227.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Ginkgo Bioworks Holdings, Inc. scores 21/100 among other emerging companies.
Ginkgo Bioworks Holdings, Inc.'s operations used $171.1M of cash in fiscal year 2025, against $319.6M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Ginkgo Bioworks Holdings, Inc. scores 67/100 among other emerging companies.
Ginkgo Bioworks Holdings, Inc.'s cash, cash equivalents and investments came to $422.6M at the end of fiscal year 2025, against $611.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Ginkgo Bioworks Holdings, Inc. scores 50/100 among other emerging companies.
Ginkgo Bioworks Holdings, Inc. scores -7.20, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($875.4M) relative to total liabilities ($611.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Ginkgo Bioworks Holdings, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Ginkgo Bioworks Holdings, Inc. reported a net loss of $313K while operations used $171.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Ginkgo Bioworks Holdings, Inc. generated $20.2M in revenue in Q2 2026. This represents a decrease of 48.5% from the same quarter a year earlier. Against the prior quarter it is up 3.5%.
Ginkgo Bioworks Holdings, Inc.'s EBITDA was -$46.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.7% from the same quarter a year earlier. Against the prior quarter it is up 21.1%.
Ginkgo Bioworks Holdings, Inc. reported -$46.7M in net income in Q2 2026. This represents an increase of 22.5% from the same quarter a year earlier. Against the prior quarter it is up 43.4%.
Not reported for Q2 2026.
Cash & Balance Sheet
Ginkgo Bioworks Holdings, Inc. recorded an outflow of $46.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 16.4% from the same quarter a year earlier. Against the prior quarter it is up 3.6%.
Ginkgo Bioworks Holdings, Inc. held $84.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Ginkgo Bioworks Holdings, Inc.'s gross margin was 91.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 5.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.4 percentage points.
Ginkgo Bioworks Holdings, Inc.'s ROE was -11.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.5 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Ginkgo Bioworks Holdings, Inc. invested $46.2M in research and development in Q2 2026. This represents a decrease of 13.4% from the same quarter a year earlier. Against the prior quarter it is down 7.4%.
Ginkgo Bioworks Holdings, Inc. invested $2.6M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 6792.1% from the same quarter a year earlier. Against the prior quarter it is up 35.5%.
Not reported for Q2 2026.
DNA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.2M-48.5% | $19.5M-49.1% | $54.0M+23.1% | $38.8M-56.4% | $39.1M-30.4% | $38.2M+0.8% | $43.8M+26.2% | $89.0M+60.6% |
| Cost of Revenue | $1.7M-68.0% | $3.1M-24.3% | N/A | N/A | $5.4M | $4.1M | N/A | N/A |
| Gross Profit | $18.4M-45.4% | $16.4M-52.0% | N/A | N/A | $33.8M | $34.1M | N/A | N/A |
| R&D Expenses | $46.2M-13.4% | $49.9M-29.6% | $50.1M-34.4% | $69.4M-9.9% | $53.4M-60.2% | $70.9M-48.0% | $76.4M-34.7% | $77.0M-50.8% |
| SG&A Expenses | $30.8M-12.0% | $37.8M-4.8% | $63.6M+11.1% | $45.0M-14.0% | $35.0M-47.2% | $39.7M-43.5% | $57.3M-35.8% | $52.3M-36.3% |
| Operating Income | -$58.5M-0.7% | -$71.4M+11.9% | -$86.1M+16.9% | -$90.0M-63.1% | -$58.2M+73.9% | -$81.0M+54.5% | -$103.6M+41.8% | -$55.2M+80.7% |
| EBITDA | -$46.2M-7.7% | -$58.6M+11.5% | -$72.5M+17.6% | -$74.8M-96.6% | -$42.9M+79.1% | -$66.2M+59.9% | -$88.0M+46.8% | -$38.0M+85.7% |
| Interest Expense | $3.2M-46.9% | $3.6M-40.9% | -$17.9M-325.3% | $5.7M+162.1% | $6.1M+159.0% | $6.1M-48.1% | $7.9M-46.7% | -$9.3M+38.4% |
| Income Tax | $128K+145.2% | -$80K-190.9% | -$643K-97.8% | $1K+100.3% | -$283K-248.9% | $88K+183.9% | -$325K-64.1% | -$375K-1604.5% |
| Net Income | -$46.7M+22.5% | -$82.6M+9.2% | $231.7M-47.2% | -$80.8M-43.2% | -$60.3M+72.2% | -$91.0M+45.2% | $438.9M-35.5% | -$56.4M+81.4% |
| EPS (Basic) | -$0.75+31.8% | -$1.39+17.3% | -$1.42+27.6% | -$1.45-34.3% | -$1.10+74.0% | -$1.68+49.2% | -$1.96+54.2% | -$1.08+82.6% |
| EPS (Diluted) | N/A | N/A | -$1.42+27.6% | -$1.45-34.3% | -$1.10 | -$1.68 | -$1.96+54.2% | -$1.08 |
| Diluted Shares (Avg) | N/A | N/A | N/A | 56M+6.5% | 55M | 54M | N/A | 52M |
DNA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $990.0M-19.6% | $1.0B-20.1% | $1.1B-18.7% | $1.2B-19.7% | $1.2B-24.3% | $1.3B-18.2% | $1.4B-17.3% | $1.5B-26.9% |
| Current Assets | $332.5M-36.4% | $410.0M-27.4% | $471.8M-21.7% | $506.1M-23.6% | $523.0M-33.2% | $564.5M-37.5% | $602.7M-39.8% | $662.5M-42.0% |
| Cash & Equivalents | $84.5M-58.5% | $143.9M-54.0% | $167.2M-70.2% | $111.1M-82.0% | $203.6M-72.1% | $312.4M-62.8% | $561.6M-40.5% | $616.2M-41.3% |
| Short-Term Investments | $0-100.0% | $0-100.0% | $255.4M | $384.4M | $355.8M | $12.8M | $0 | $0 |
| Accounts Receivable | $13.0M-41.3% | $19.8M-24.6% | $24.0M+9.9% | $21.4M-8.5% | $22.2M+19.2% | $26.3M+8.7% | $21.9M+27.4% | $23.4M-62.2% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $0-100.0% |
| Total Liabilities | $569.8M-7.8% | $589.9M-8.7% | $611.1M-7.6% | $629.4M-7.8% | $618.1M-22.0% | $646.0M+8.7% | $661.4M+16.4% | $682.9M-11.7% |
| Current Liabilities | $72.7M-24.8% | $79.6M-31.2% | $96.0M-10.5% | $115.3M+0.7% | $96.7M-41.8% | $115.7M-31.6% | $107.3M-34.5% | $114.4M-32.1% |
| Non-Current Liabilities | $497.0M-4.7% | $510.3M-3.8% | $515.1M-7.0% | $514.1M-9.6% | $521.3M-16.7% | $530.4M+24.7% | $554.1M+37.0% | $568.5M-6.1% |
| Total Equity | $420.3M-31.4% | $443.2M-31.6% | $508.6M-29.0% | $559.8M-29.8% | $613.0M-26.4% | $647.4M-34.4% | $716.1M-34.7% | $797.9M-36.3% |
| Retained Earnings | -$6.3B-4.9% | -$6.2B-5.1% | -$6.2B-5.4% | -$6.1B-5.9% | -$6.0B-5.6% | -$5.9B-8.7% | -$5.8B-10.3% | -$5.7B-12.8% |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
DNA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$44.3M-10.0% | -$46.7M+9.4% | -$47.7M-12.4% | -$31.6M+69.5% | -$40.3M+52.3% | -$51.5M+42.3% | -$42.4M+26.6% | -$103.5M-40.7% |
| Depreciation & Amortization | $12.3M-19.2% | $12.8M-13.6% | $13.7M-12.7% | $15.3M-11.1% | $15.2M-12.0% | $14.8M+15.2% | $15.7M+21.9% | $17.2M-18.5% |
| Stock-Based Compensation | $7.6M-59.6% | $15.9M-8.8% | N/A | $17.8M+28.8% | $18.8M-49.4% | $17.4M-57.4% | N/A | $13.9M-73.6% |
| Capital Expenditures | $2.6M+6792.1% | $1.9M-74.6% | $5K-100.0% | $0-100.0% | $38K-99.9% | $7.6M+13.6% | $13.7M+297.9% | $15.1M+244.4% |
| Free Cash Flow | -$46.9M-16.4% | -$48.6M+17.8% | -$47.7M+15.1% | -$31.6M+73.3% | -$40.3M+63.8% | -$59.1M+38.4% | -$56.1M+8.4% | -$118.6M-52.2% |
| Investing Cash Flow | $11.1M+117.4% | $23.1M+111.6% | $95.1M+826.8% | -$72.8M-613.9% | -$63.9M-138.0% | -$198.7M-1540.7% | -$13.1M+72.0% | -$10.2M-201.7% |
| Financing Cash Flow | $16.5M+16925.5% | -$19K+90.8% | $8.1M+4110.8% | $9.9M+2237.2% | -$98K+56.6% | -$207K+75.5% | -$203K+67.9% | -$465K-47.6% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
DNA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.5%+5.2pp | 84.1%-5.2pp | N/A | N/A | 86.3% | 89.3% | N/A | N/A |
| Operating Margin | -290.5% | -366.5% | -159.6% | -231.8% | -148.6% | -211.8% | -236.3% | -62.0% |
| Net Margin | -231.7% | -424.1% | 429.4% | -207.9% | -154.1% | -237.9% | 1001.1% | -63.3% |
| Return on Equity | -11.1%-1.3pp | -18.6%-4.6pp | 45.6%-15.7pp | -14.4%-7.4pp | -9.8%+16.2pp | -14.1%+2.8pp | 61.3%-0.7pp | -7.1%+17.1pp |
| Return on Assets | -4.7%+0.2pp | -8.0%-1.0pp | 20.7%-11.2pp | -6.8%-3.0pp | -4.9%+8.5pp | -7.0%+3.5pp | 31.9%-9.0pp | -3.8%+11.1pp |
| Current Ratio | 4.57-0.8x | 5.15+0.3x | 4.92-0.7x | 4.39-1.4x | 5.41+0.7x | 4.88-0.5x | 5.62-0.5x | 5.79-1.0x |
| Debt-to-Equity | 1.36+0.3x | 1.33+0.3x | 1.20+0.3x | 1.12+0.3x | 1.01+0.1x | 1.00+0.4x | 0.92+0.4x | 0.86+0.2x |
| Asset Turnover | 0.020.0x | 0.020.0x | 0.050.0x | 0.030.0x | 0.030.0x | 0.030.0x | 0.030.0x | 0.060.0x |
| FCF Margin | -232.6% | -249.7% | -88.4% | -81.4% | -103.0% | -154.7% | -128.1% | -133.2% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc. DNA | FY2025 | $170.2M | -$313K | -0.2% | $875.4M | 54/100 |
| AnaptysBio, Inc. ANAB | FY2025 | $234.6M | -$13.2M | -5.6% | $1.4B | 80/100 |
| MeiraGTx Holdings plc MGTX | FY2025 | $81.4M | -$114.2M | N/A | $1.0B | 62/100 |
| Xencor, Inc. XNCR | FY2025 | $125.6M | -$91.9M | -73.2% | $1.8B | 40/100 |
| Septerna, Inc. SEPN | FY2025 | $46.0M | -$48.9M | N/A | $1.8B | 47/100 |
| Keros Therapeutics, Inc. KROS | FY2025 | $243.9M | $87.0M | 35.7% | $236.9M | 91/100 |
Where Ginkgo Bioworks Holdings, Inc. Ranks
Frequently Asked Questions
What is Ginkgo Bioworks Holdings, Inc.'s annual revenue?
Ginkgo Bioworks Holdings, Inc. (DNA) reported $170.2M in total revenue for fiscal year 2025. This represents a -25.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ginkgo Bioworks Holdings, Inc.'s revenue growing?
Ginkgo Bioworks Holdings, Inc. (DNA) revenue declined by 25.1% year-over-year, from $227.0M to $170.2M in fiscal year 2025.
Is Ginkgo Bioworks Holdings, Inc. profitable?
No, Ginkgo Bioworks Holdings, Inc. (DNA) reported a net income of -$313K in fiscal year 2025, with a net profit margin of -0.2%.
What is Ginkgo Bioworks Holdings, Inc.'s EBITDA?
Ginkgo Bioworks Holdings, Inc. (DNA) had EBITDA of -$256.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Ginkgo Bioworks Holdings, Inc.'s net profit margin?
Ginkgo Bioworks Holdings, Inc. (DNA) had a net profit margin of -0.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Ginkgo Bioworks Holdings, Inc.'s return on equity (ROE)?
Ginkgo Bioworks Holdings, Inc. (DNA) has a return on equity of -0.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Ginkgo Bioworks Holdings, Inc.'s free cash flow?
Ginkgo Bioworks Holdings, Inc. (DNA) recorded an outflow of $178.7M in free cash flow during fiscal year 2025. This represents a 53.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ginkgo Bioworks Holdings, Inc.'s operating cash flow?
Ginkgo Bioworks Holdings, Inc. (DNA) recorded an outflow of $171.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Ginkgo Bioworks Holdings, Inc.'s total assets?
Ginkgo Bioworks Holdings, Inc. (DNA) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Ginkgo Bioworks Holdings, Inc.'s capital expenditures?
Ginkgo Bioworks Holdings, Inc. (DNA) invested $7.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Ginkgo Bioworks Holdings, Inc. spend on research and development?
Ginkgo Bioworks Holdings, Inc. (DNA) invested $243.8M in research and development during fiscal year 2025.
What is Ginkgo Bioworks Holdings, Inc.'s current ratio?
Ginkgo Bioworks Holdings, Inc. (DNA) had a current ratio of 4.92 as of fiscal year 2025, which is generally considered healthy.
What is Ginkgo Bioworks Holdings, Inc.'s debt-to-equity ratio?
Ginkgo Bioworks Holdings, Inc. (DNA) had a debt-to-equity ratio of 1.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ginkgo Bioworks Holdings, Inc.'s return on assets (ROA)?
Ginkgo Bioworks Holdings, Inc. (DNA) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Ginkgo Bioworks Holdings, Inc.'s P/E ratio?
Ginkgo Bioworks Holdings, Inc. (DNA) trades at 40.4x earnings, its market capitalization divided by net income of $21.6M net income, trailing 12 months to June 30, 2026. The market capitalization is $875.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Ginkgo Bioworks Holdings, Inc.'s price-to-sales ratio?
Ginkgo Bioworks Holdings, Inc. (DNA) trades at 6.6x sales, its market capitalization divided by revenue of $132.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $875.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Ginkgo Bioworks Holdings, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Ginkgo Bioworks Holdings, Inc. (DNA) held $422.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $171.1M over that year. Dividing the one by the other, the reported balance equals about 30 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Ginkgo Bioworks Holdings, Inc.'s Altman Z-Score?
Ginkgo Bioworks Holdings, Inc. (DNA) has an Altman Z-Score of -7.20, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Ginkgo Bioworks Holdings, Inc.'s Piotroski F-Score?
Ginkgo Bioworks Holdings, Inc. (DNA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ginkgo Bioworks Holdings, Inc.'s earnings high quality?
Ginkgo Bioworks Holdings, Inc. (DNA) reported a net loss of $313K while operations used $171.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Ginkgo Bioworks Holdings, Inc.?
Ginkgo Bioworks Holdings, Inc. (DNA) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.